Claims
- 1. Antigenic peptide compounds binding to LDH-C.sub.4 antiserum, comprising the class of linear peptide compounds containing the antigenic domain V-L-D-M and being selected from the sequences of N-terminal to C-terminal amino acids represented by:
- (a) Q-V-V-E-G-G-Y-E-V-L-D-M-K,
- (b) Q-V-V-E-G-G-Y-E-V-L-D-M,
- (c) V-V-E-G-G-Y-E-V-L-D-M-K,
- (d) V-V-E-G-G-Y-E-V-L-D-M,
- (e) V-E-G-G-Y-E-V-L-D-M-K,
- (f) V-E-G-G-Y-E-V-L-D-M,
- (g) E-G-G-Y-E-V-L-D-M-K,
- (h) E-G-G-Y-E-V-L-D-M,
- (i) G-G-Y-E-V-L-D-M-K,
- (j) G-G-Y-E-V-L-D-M,
- (k) G-Y-E-V-L-D-M-K,
- (l) G-Y-E-V-L-D-M,
- (m) Y-E-V-L-D-M-K,
- (n) Y-E-V-L-D-M,
- (o) E-V-L-D-M-K,
- (p) E-V-L-D-M,
- (q) V-L-D-M-K, and
- (r) V-L-D-M.
- wherein G represents glycine, and Q, V, E, Y, L, D, M, and K, respectively represent the L-amino acid forms of glutamine, valine, glutamic acid, tyrosine, leucine, aspartic acid, methionine, and lysine.
- 2. The peptide compound (a) of claim 1.
- 3. The peptide compound (b) of claim 1.
- 4. The peptide compound (c) of claim 1.
- 5. The peptide compound (d) of claim 1.
- 6. The peptide compound (e) of claim 1.
- 7. The peptide compound (f) of claim 1.
- 8. The peptide compound (g) of claim 1.
- 9. The peptide compound (h) of claim 1.
- 10. The peptide compound (i) of claim 1.
- 11. The peptide compound (j) of claim 1.
- 12. The peptide compound (k) of claim 1.
- 13. The peptide compound (l) of claim 1.
- 14. The peptide compound (m) of claim 1.
- 15. The peptide compound (n) of claim 1.
- 16. The peptide compound (o) of claim 1.
- 17. The peptide compound (p) of claim 1.
- 18. The peptide compound (q) of claim 1.
- 19. The peptide compound (r) of claim 1.
GRANT REFERENCE
This invention was developed in part under Grant HD 05863 by the National Institute of Health.
US Referenced Citations (3)